Want to Collect a High Dividend Every Month? Invest in These 3 Stocks

AbbVie, Medtronic, and Enbridge are highlighted as high-yield dividend stocks paying 3.3%, 3.6%, and 5.2%, respectively, with cash flow coverage described as strong. AbbVie generated $17.8 billion in free cash flow versus $11.7 billion in dividends, while Medtronic produced $5.4 billion in free cash flow against $3.6 billion in payouts. Enbridge’s 2025 distributable cash flow rose 4% to C$12.5 billion and it has raised its dividend for 31 straight years, supporting the article’s case for monthly income diversification.

Analysis

The key market signal is not the dividend itself but the implied preference for defensive compounders with visible cash conversion in a late-cycle, higher-for-longer rate regime. ABBV and MDT screen as quality duration trades: both are effectively bond proxies with embedded operating upside, so they should continue to attract income and low-volatility capital if the macro stays choppy. ENB is the most rate-sensitive asset in the group, but its valuation should stay supported as long as long-bond yields remain range-bound and energy transport volumes hold up; the article’s yield framing understates how much of ENB’s appeal is actually scarcity value among large-cap cash-yield names.

Second-order, the “monthly income” pitch can create incremental bid support from retail and income allocators, but it also narrows forward return expectations. Once a stock is packaged as a dividend sleeve rather than an operating story, upside multiple expansion becomes harder unless there is a clear earnings beat or a dividend-growth catalyst. That favors ABBV and MDT, where operating execution can still surprise, and it makes ENB more vulnerable to a simple yield-compression trade if rates fall or crude stabilizes and investors rotate into lower-risk fixed income.

The contrarian miss is that these are not equivalent income assets: ABBV and MDT have idiosyncratic business momentum, while ENB is primarily a regulated/throughput-plus-rate instrument. If healthcare sentiment weakens or a patent/launch setback hits ABBV, the stock can de-rate quickly despite the dividend; conversely, if rates back up, ENB can underperform even with stable cash flow. Over the next 3-6 months, the best risk/reward is likely in relative-value rather than outright long-only yield chasing.

Key Decisions for Investors

• Long ABBV / short ENB for 1-3 months: expresses quality cash-flow growth vs rate sensitivity; target 6-8% relative outperformance if rates drift higher or risk appetite rotates back to healthcare.
• Buy MDT on pullbacks over the next 2-4 weeks: use it as a defensive compounder with lower headline risk than ENB; risk/reward improves if the market continues to pay up for visible free-cash-flow coverage.
• Sell covered calls on ENB into strength for the next quarterly cycle: monetize yield demand while capping upside, since the stock is more exposed to multiple compression if bond yields soften.
• If ABBV approaches a post-earnings volatility window, consider a call spread rather than outright long: upside is more likely to come from execution beats than multiple expansion, limiting premium bleed.
• For income-oriented portfolios, pair ABBV + MDT rather than chasing ENB alone: better diversification of catalyst risk and less dependence on commodity or rate moves.